Publications by authors named "Roberto Labianca"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,016

Total Likes

58

Extended Reach

70,770

Social Features

25
D
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Axel Grothey, Alberto F Sobrero, Anthony F Shields, Takayuki Yoshino, James Paul, Julien Taieb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca

N Engl J Med· March 2018

Videos about Article: user user user

3 17 22 5 118 2

View All Article and Social Media Activity
D
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Axel Grothey, Alberto F Sobrero, Anthony F Shields, Takayuki Yoshino, James Paul, Julien Taieb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca

N Engl J Med· March 2018

Videos about Article: user user user

3 17 22 5 118 2

View All Article and Social Media Activity
T
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.
Alessandro Pastorino, Heshan Liu, Levi Pederson, Valentino Martelli, Timothy Iveson, Roberto Labianca

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy.
Marina Marchetti, Patricia Gomez-Rosas, Laura Russo, Carmen Julia Tartari, Silvia Bolognini, Roberto Labianca

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer.
Patricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, Laura Russo, Sara Gamba, Roberto Labianca

J Thromb Haemost· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating knowledge into policy: Organizational model and minimum requirements for the implementation of a regional pancreas unit network.
Gianpaolo Balzano, Michele Reni, Maria Di Bartolomeo, Marta Scorsetti, Augusto Caraceni, Roberto Labianca

Dig Liver Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
Claire Gallois, Qian Shi, Levi D Pederson, Thierry André, Timothy J Iveson, Roberto Labianca

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.
Julien Taieb, Debora Basile, Jenny Seligmann, Guillem Argiles, Thierry André, Roberto Labianca

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.
Patricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, Cristina Verzeroli, Sara Gamba, Roberto Labianca

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Cristina Verzeroli, Cinzia Giaccherini, Laura Russo, Silvia Bolognini, Sara Gamba, Roberto Labianca

J Thromb Haemost· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Roberto Labianca

EClinicalMedicine· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Claire Gallois, Qian Shi, Jeffrey P Meyers, Timothy Iveson, Steven R Alberts, Roberto Labianca

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer.
Cinzia Giaccherini, Cristina Verzeroli, Laura Russo, Sara Gamba, Carmen Julia Tartari, Roberto Labianca

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curative treatments for colon cancer during the COVID-19 pandemic era.
Fausto Petrelli, Roberto Labianca, Alberto Zaniboni

Tumori· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Gerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, Carla Codecà, Michele Prisciandaro, Roberto Labianca

Gastric Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.
Niki Christou, Elisabeth S Bergen, Clemence Canton, Karine Le Malicot, Maria Di Bartolomeo, Roberto Labianca

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study.
Eleonora Lai, Marco Puzzoni, Pina Ziranu, Chiara Cremolini, Sara Lonardi, Roberto Labianca

Clin Colorectal Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
Elisa Fontana, Jeff Meyers, Alberto Sobrero, Timothy Iveson, Anthony F Shields, Roberto Labianca

J Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
Richard Adams, Kaitlyn Goey, Benoist Chibaudel, Miriam Koopman, Cornelis Punt, Roberto Labianca

Cancer Treat Rev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Gerardo Rosati, Sara Lonardi, Fabio Galli, Maria Di Bartolomeo, Monica Ronzoni, Roberto Labianca

Eur J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Stefano Cascinu, Rossana Berardi, Roberto Bianco, Domenico Bilancia, Alberto Zaniboni, Roberto Labianca

Eur J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang-Shu Ou, Roberto Labianca

J Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
Thierry André, Jeffrey Meyerhardt, Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Roberto Labianca

Lancet Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Roberto Labianca

Ther Adv Med Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer-Reply.
Alberto Zaniboni, Fausto Petrelli, Roberto Labianca

JAMA Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer.
Alice Labianca, Tommaso Bosetti, Alice Indini, Giorgia Negrini, Roberto Francesco Labianca

Cancers (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis